Search results
Showing 1 to 15 of 72 results for menopause
This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.
This quality standard covers diagnosing and managing menopause in women, including women who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopausal symptoms
- Quality statement 5: Information for women having treatment likely to cause menopause
- About this quality standard
All NICE products on menopause. Includes any guidance and quality standards.
In development [GID-NG10241] Expected publication date: TBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]
In development [GID-TA11058] Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.
View recommendations for IPG738Show all sections
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
complications and their babies - Breech presenting in labour Menopause: diagnosis and management Update in progress: Major update...
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
NICE Guideline (NG23), Menopause: diagnosis and management, was published in November 2015 and made clear
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917
Awaiting development [GID-TA11428] Expected publication date: TBC
This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.
Awaiting development [GID-TA11059] Expected publication date: TBC